Improving immunization coverage and equity - technical resources
Comparing Resources
Tip: You can share the address of this page to allow others to view your comparison
| Resource | Considerations for Pneumococcal Conjugate Vaccine (PCV) Product Choice |
|---|---|
| Purpose | Summary of current technical and programmatic information on WHO Prequalified PCV products to facilitate informed country choices for PCV introduction or product switch for childhood immunization programmes. |
| Content | This document is includes information on WHO position on pneumococcal vaccines in infants in children; vaccine characteristics; safety; PCV performance; programmatic considerations; cost and financial considerations; availability and supply; prioritization among new vaccine introduction decisions. |
| Use | Does not require user input. Easily accessible list. |
| Contraints/Limitations | This document should be seen as a summary, rather than an endorsement of the use of specific branded products over others. |
| Example criteria this resource could address | Cold chain volume per fully immunized child in cm3, etc. |
| If available, notes on the development process | The document is based on published sources except for content related to the newest prequalified product, PNEUMOSIL where the manufacturer provided the unpublished Clinical Study Report confidentially. The document should not be viewed as formal WHO recommendations or guidelines. |
| Additional Links | |
| Link to access the resource | /en/component/content/article/considerations-for-pneumococcal-conjugate-vaccine-pcv-product-choice?catid=653&Itemid=101 |